Retrospective Cohort Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2019; 11(6): 489-498
Published online Jun 15, 2019. doi: 10.4251/wjgo.v11.i6.489
Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma
Wen-Heng Zheng, Tao Yu, Ya-Hong Luo, Ying Wang, Ye-Fu Liu, Xiang-Dong Hua, Jie Lin, Zuo-Hong Ma, Fu-Lu Ai, Tian-Lu Wang
Wen-Heng Zheng, Tao Yu, Ya-Hong Luo, Ying Wang, Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Ye-Fu Liu, Xiang-Dong Hua, Zuo-Hong Ma, Department of Hepatobiliary and Pancreatic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Jie Lin, Fu-Lu Ai, Department of General Surgery (VIP ward), Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Tian-Lu Wang, Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Author contributions: Zheng WH was responsible for study design, data collection and analysis, and manuscript writing and proofreading; Yu T was responsible for study design and manuscript writing and proofreading; Luo YH and Wang Y performing the research and data analysis; Liu YF, Hua XD, and Lin J performed data collection and proofreading; Ma ZH, Ai FL, and Wang TL performed data analysis.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of the Liaoning Cancer Hospital.
Informed consent statement: Informed consent was waived by the Institutional Review Board of the Liaoning Cancer Hospital because this study is a retrospective study.
Conflict-of-interest statement: None of the authors has any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Tao Yu, MD, PhD, Chief Doctor, Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, China. yutao@cancerhosp-ln-cmu.com
Telephone: +86-18900917557 Fax: +86-24-24315679
Received: March 7, 2019
Peer-review started: March 8, 2019
First decision: May 13, 2019
Revised: May 15, 2019
Accepted: May 28, 2019
Article in press: May 29, 2019
Published online: June 15, 2019
Core Tip

Core tip: In this study, hilar cholangiocarcinoma patients with obstructive jaundice were observed by different methods of reducing jaundice. The effectiveness of transcatheter arterial chemoembolization combined with radiotherapy was observed in extending the effective drainage time of the stent or drainage tube, improving the quality of life, and changing the prognosis of patients. The independent factors affecting survival were analyzed. The results may be helpful to improve the systematic palliative treatment of hilar cholangiocarcinoma.